Redeye was a bit surprised by the dip in gross margins in the second quarter.
- Q2 EBIT 4% below FactSet consensus on lower margin - We lower our '24e-'26e EBIT estimates by 7-3%...
Incap upgraded its 2024 full year guidance. Net sales is now guided to grow (previously decline) in ...
Redeye see a Q2 report from Stille aligning with our estimates in terms of both sales and profitabil...
Redeye states that the Q2 report came in above its estimates on both sales and EBITDA.
- Sales +3% and adj. EBIT +18% vs. ABGSCe - Operating cash flow SEK -19m, vs ABGSCe SEK -80m - Minor...
Redeye provides its initial take on ADDvise’s Q2 2024 report, which came in broadly below our estima...
Redeye comments on SHH´s second quarter of the year.
Redeye retains its positive view on Lagercrantz following a Q1 report in-line with our estimates.
Fiskars Q2 adjusted EBIT of EUR 19.2m came 3% above LSEG Data & Analytics consensus expectations.
Redeye comments on the Q2 report released earlier this morning.
- Net sales SEK 562m, 0% vs ABGSCe and Factset cons.
Doro delivered better than expected Q2 report on all key metrics.
Atria reported Q2 adjusted EBIT of EUR 18.4m, 47% (EUR 5.
Redeye raises its forecasts and Base Case following Hexatronic’s Q2 report, showing a solid sequenti...
- '24e-'26e adj. EBITA down 3-2% - Increasingly likely that Q3'24 will be the trough - NTM EV/EBITA ...
- Q2e: 21% ARR growth and adj. EBITDA of DKK 1.1m - '24e likely to be even more back-end loaded vs.
Redeye strengthens its positive view of Vertiseit following a Q2 report that exceeds our expectation...
Redeye endorses today’s news that the ETA (“European Thyroid Association”) recommends Emcitate as a ...
Cibus posted Q2 results largely in line with expectations.